Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Terminated 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Head & Neck 1Genitourinary 1Gastrointestinal 1Dermatologic 1

Conditions

Squamous Cell Carcinoma of Head and Neck 1Small Cell Lung Carcinoma 1Prostatic Neoplasms 1Melanoma 1Esophageal Squamous Cell Carcinoma 1Carcinoma, Non-Small-Cell Lung 1

Interventions

pembrolizumab 50Nivolumab 21Docetaxel 11atezolizumab 7Ipilimumab 7avelumab 6Cyclophosphamide 6Paclitaxel 5Cetuximab 5Carboplatin 5fludarabine 4Radiotherapy 4Gemcitabine 4utomilumab 3spartalizumab 3lenvatinib 3durvalumab 3Trastuzumab 3Specimen Handling 3Interleukin-2 3Cisplatin 3Bevacizumab 3Albumin-Bound Paclitaxel 3zimberelimab 2tremelimumab 2tisotumab vedotin 2tislelizumab 2sargramostim 2obinutuzumab 2epacadostat 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Squamous Cell Carcinoma of Head and Neck × SGN-LIV1A × Genitourinary × Clear all
NCT04032704 2025-03-10

A Study of Ladiratuzumab Vedotin in Advanced Solid Tumors

Seagen Inc.

Phase 2 Terminated
205 enrolled 54 charts
DermatologicGastrointestinalGenitourinaryHead & NeckThoracic

Squamous Cell Carcinoma of Head and Neck, Esophageal Squamous Cell Carcinoma, Carcinoma, Non-Small-Cell Lung, Melanoma, Prostatic Neoplasms, Small Cell Lung Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡